Adjustments for Non-Cash Items [USD, Millions]

Stock-Based Compensation [USD, Millions]

Changes in Working Capital [USD, Millions]

Capital Expenditures (CapEx) [USD, Millions]

Proceeds from / Repayments of Debt [USD, Millions]

Share Repurchases [USD, Millions]

Dividend Payments [USD, Millions]

Net Change in Cash [USD, Millions]

e744ecdd5709ab4e85e430d2f45e8e33d5a2b7ed21269f07c949b568fb8cd2ef

Total Revenue [USD, Millions]

Cost of Goods Sold (COGS) [USD, Millions]

Selling, General, and Administrative Expenses (SG&A) [USD, Millions]

Research and Development (R&D) [USD, Millions]

Depreciation and Amortization (D&A) [USD, Millions]

Interest Expense [USD, Millions]

Operating Income (EBIT) [USD, Millions]

Net Income [USD, Millions]

Earnings Per Share (EPS) - Basic [USD]

Earnings Per Share (EPS) - Diluted [USD]

aa94b6ee4a07a0fe2fb726f1131b373df34813659d36015ec314b09e3658bf67

Americas

Europe

Asia Pacific

- United States

- China including Hong Kong

- Rest of the World

Total Revenue

2a2db731c2898458cfa4c50d358f712fc75a16402a82a4b65c9362fb14e614b4

Days sales outstanding (days)

Inventory days on-hand (days)

17a8a9d00312400f38a481cbc56ebf2296460c9bd398369d7127cb65576965fc

Net Revenue - Products (USD, millions)

Net Revenue - Services and Other (USD, millions)

Total Net Revenue (USD, millions)

Cost of Products (USD, millions)

Cost of Services and Other (USD, millions)

Total Costs (USD, millions)

Research and Development (USD, millions)

Selling, General and Administrative (USD, millions)

Total Costs and Expenses (USD, millions)

Income from Operations (USD, millions)

Interest Income (USD, millions)

Interest Expense (USD, millions)

Other Income (Expense), Net (USD, millions)

Income Before Taxes (USD, millions)

Provision for Income Taxes (USD, millions)

Net Income (USD, millions)

Net Income per Share - Basic (USD)

Net Income per Share - Diluted (USD)

Weighted Average Shares Used in Computing Net Income per Share - Basic (millions)

Weighted Average Shares Used in Computing Net Income per Share - Diluted (millions)

d0712c2b454f206df96306e92412ccf816d0a797d2550f897ddbfeccb972bd66

Cash and cash equivalents (USD, millions)

Accounts receivable, net (USD, millions)

Inventory (USD, millions)

Other current assets (USD, millions)

Total current assets (USD, millions)

Property, plant and equipment, net (USD, millions)

Goodwill (USD, millions)

Other intangible assets, net (USD, millions)

Long-term investments (USD, millions)

Other assets (USD, millions)

Total assets (USD, millions)

Accounts payable (USD, millions)

Employee compensation and benefits (USD, millions)

Deferred revenue (USD, millions)

Short-term debt (USD, millions)

Other accrued liabilities (USD, millions)

Total current liabilities (USD, millions)

Long-term debt (USD, millions)

Retirement and post-retirement benefits (USD, millions)

Other long-term liabilities (USD, millions)

Total liabilities (USD, millions)

Common stock (USD, millions)

Additional paid-in-capital (USD, millions)

Retained earnings (USD, millions)

Accumulated other comprehensive loss (USD, millions)

Total stockholders' equity (USD, millions)

Total liabilities and stockholders' equity (USD, millions)

dbad5ec350f5cf976f2911484cb6d11e58a08d2c6f47461d6117aa745edd8c9c

The **Net Revenue - Products** decline in **FY 2024** occurred mainly due to **customer capital expenditure pressures**—notably in the **pharmaceutical market** affecting the **life sciences**, **applied**, and **diagnostics & genomics** segments—as well as **weakness in key product lines** such as **Liquid Chromatography (LC)**, **Mass Spectrometry (MS)**, **Cell Analysis**, and **Nucleic Acid Solutions**. Additionally, there was **geographic weakness** (especially in the **Americas** and **Asia Pacific, including China**) and, while there was some offset from **growth in consumables and pathology businesses**, the overall effect was a **7% decline** in product revenue. Foreign currency movements, however, did not impact the revenue growth.  **[0001090872-24-000049_a-20241031.htm:66]** **[0001090872-24-000049_a-20241031.htm:67]** 

Why did Net Revenue - Products drop in FY 2024?

The significant **EPS jump** in Q3 2024 was driven by several factors. Firstly, **net income increased** dramatically from **$111 million** in Q3 2023 to **$282 million** in Q3 2024, boosting the net income per share from **$0.38** to **$0.97**. Additionally, **effective cost management** and **operational efficiency improvements** helped offset a decline in revenue, contributing to better margins. Lastly, **strategic transformation initiatives** and **investments in growth opportunities** enhanced operational performance, further driving the EPS increase.  **[0001090872-24-000024_exhibit991-q324pressrelease.htm:4]** **[0001090872-24-000033_a-20240731.htm:1]** 

What factors drove the EPS jump in Q3 2024?

Income from Operations in Q3 2024 is significantly higher primarily because of a combination of **restructuring charges** that positively impacted the period, alongside a relative absence of the adverse **asset impairment charges** that affected Q3 2023. Additionally, there was a boost from higher **interest income** (rising from **$13 million** to **$19 million**) due to increased cash balances and higher rates, and effective **cost management** helped reduce expenses, contributing to the overall gain of **$200 million or 151%** over Q3 2023.  **[0001090872-24-000033_a-20240731.htm:49]** **[0001090872-24-000033_a-20240731.htm:54]** **[0001090872-24-000033_a-20240731.htm:48]** 

Why is Income from Operations much higher in Q3 2024?

The tax provision turned positive in Q4 2024 because the company experienced a significant increase in its effective tax rate—from **7.4%** in Q4 2023 to **15.3%** in Q4 2024. This change was largely due to the elimination of a sizable federal tax benefit stemming from a realized loss on a divestiture, which had previously contributed to a tax benefit in 2023. In addition, the impact of a **$47 million** tax benefit related to foreign-derived intangible income and a less favorable adjustment in the Singapore tax holiday—where the benefit decreased compared to the prior period—further contributed to turning the tax treatment from a benefit to a positive provision.  **[0001090872-24-000049_a-20241031.htm:124]** **[0001090872-24-000049_a-20241031.htm:71]** 

What caused the tax provision to turn positive in Q4 2024?

1c50c401d75608b918ee031f8a0c22983ed527c348f3a07e093db9b1808f1cfb

The documents indicate that no single definitive reason is provided for the lower cash balance in Q4 2024. However, several financial activities likely contributed to the reduction in cash and cash equivalents to **$1,329 million**. These include **capital expenditures of $93 million**, over **$400 million** in shareholder returns (including **$335 million** in share repurchases and **$68 million** in dividends), and the acquisition of BIOVECTRA, even though the company generated a strong operating cash flow of **$1.75 billion**. These activities collectively could explain why the cash reserve was lower during that period.  **[0001090872-24-000049_a-20241031.htm:91]** **[0001090872-24-000042_exhibit991-q424pressrelease.htm:4]** **[A_3409990_5]** 

Why was Cash and cash equivalents so low in Q4 2024?

The sharp increase in total assets in Q4 2024 was driven by strategic acquisitions and investments. **Goodwill** saw a notable rise, primarily due to the BIOVECTRA acquisition, which added **$526 million** to goodwill, while **property, plant, and equipment, other assets, and other intangible assets** also experienced significant increases that collectively boosted the total asset value.  **[0001090872-24-000049_a-20241031.htm:91]** **[0001090872-24-000049_a-20241031.htm:130]** 

What drove the sharp increase in Total assets in Q4 2024?

The jump in **long-term debt** during Q4 2024 was driven by several factors. Specifically, the company issued **$600 million of 2027 Senior Notes at a 4.20% interest rate** and **$600 million of 2034 Senior Notes at a 4.75% interest rate**, repaid **$600 million of its term loan facility**, and assumed **$18 million and $1 million in long-term debt** related to the BIOVECTRA acquisition. These actions collectively resulted in a net increase of **$610 million** compared to the previous year.  **[0001090872-24-000049_a-20241031.htm:83]** **[0001090872-24-000049_a-20241031.htm:154]** 

What caused the sudden jump in Long-term debt in Q4 2024?

d94dd48c971fb68a52ee6806901070503144f17e45fb9906b1e2b88fb7d5a085

Life Sciences and Applied Markets

Diagnostics and Genomics

Agilent CrossLab

- Products

- Services and Other

- Analytical Lab Consumables

- Diagnostics and Genomics Solutions

- Informatics and Other

7f7d8f04c2ece47a28846262bd0dc5f72652ca3495dd9e1964014e64b449163c

1882e74f6b2dc675b94e5cb0b2aaa54e9198776841b1558fcac2f457e6b57f6d

Agilent Technologies Inc (A)

Financials